Loading patent…
OwnerRyuichi Morishita, Hiromi Koike +2inventors
InventorsRyuichi Morishita, Hiromi Koike, Tadashi Tanabe, Motokuni Aoki
Estimating the term…
The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
A pharmaceutical composition for angiogenic therapy which contains, as the active ingredients, at least one substance selected from the group of:
A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of a gene encoding an angiogenesis factor with at least one substance selected from the group of:
A pharmaceutical composition for angiogenic therapy which contains HGF gene and prostacyclin synthase gene as the active ingredients.
A pharmaceutical composition for angiogenic therapy which is characterized by the combined use of HGF gene and prostacyclin synthase gene.
A pharmaceutical composition for angiogenic therapy which contains VEGF gene and prostacylin synthase gene as the active ingredients.
A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of VEGF gene and prostacyclin synthase gene.
An agent for potentiating the angiogenic effect due to a gene encoding an angiogenesis factor which contains, as the active ingredient, at least one substance selected from the group of:
An agent for potentiating the angiogenic effect due to HGF gene which contains prostacyclin synthase gene as the active ingredient.
An angiogenic agent which contains prostacyclin synthase gene as the active ingredient.
A pharmaceutical composition for angiogenic therapy which contains ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients.
A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of ets-1 gene and another gene encoding an angiogenesis factor.
A pharmaceutical composition for angiogenic therapy which contains HGF gene and ets-1 gene as the active ingredients.
A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of HGF gene and ets-1 gene.
An agent containing ets-1 gene as the active ingredient that potentiates the angiogenic effect due to another gene encoding an angiogenesis factor.
An agent for potentiating the angiogenic effect due to HGF gene, which contains ets-1 gene as the active ingredient.
An angiogenic agent which contains ets-1 gene as the active ingredient.
Dependencies are inferred from the claim text.